Skip to main content

Table 1 Summary of baseline characteristics for each trial

From: Interpreting small treatment differences from quality of life data in cancer trials: an alternative measure of treatment benefit and effect size for the EORTC-QLQ-C30

 

TOPICAL (N = 670)

SOCCAR (N = 130)

Study 10 (N = 241)

Study 11 (N = 422)

Study 12 (N = 724)

Study 14 (N = 722)

Age (Median, range)

77 (72–82)

62 (39–75)

62 (27–81)

62 (34–81)

65 (38–86)

62 (33–84)

Gender:

      

Male

409 (61 %)

79 (61 %)

136 (56 %)

296 (70 %)

412 (57 %)

465 (64 %)

Female

261 (39 %)

51 (39 %)

105 (43 %)

126 (30 %)

312 (43 %)

257 (36 %)

ECOG: 0–1

106 (16 %)

130 (100 %)

164 (68 %)

365 (86 %)

529 (73 %)

648 (90 %)

2

372 (56 %)

0

60 (25 %)

48 (11 %)

153 (21 %)

74 (10 %)

3

192 (29 %)

0

17 (7 %)

9 (21 %)

42 ( 6 %)

0

Stage: IIIa-IIIb

234 (35 %)

130 (100 %)

103 (43 %)

200 (47 %)

368a(51 %)

322 (45 %)

IV

436 (65 %)

0

138 (57 %)

222 (53 %

356a(49 %)

400 (55 %)

  1. alimited disease n = 368, extensive disease n = 356
  2. Eastern Co-operative Oncology Group (ECOG) status:
  3. 0: Fully active, able to carry on all pre-disease performance without restriction
  4. 1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work
  5. 2 Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50 % of waking hours
  6. 3 Capable of only limited self-care, confined to bed or chair more than 50 % of waking hours
  7. 4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
  8. 5 Dead